Reliant Pharmaceuticals Inc. has filed a patent infringement suit in the U.S. District Court for the District of Delaware against Par Pharmaceutical Inc. alleging infringement of Orange Book listed U.S. Patent # 5,681,588 for antiarrhythmic drug Rythmol SR, generically propafenone hydrochloride extended release capsule. The lawsuit is result of Par’s notification that it has filed a Para IV certification in connection with its abbreviated new drug application (ANDA) to the US FDA seeking marketing approval for generic Rythmol SR before expiry of O.B. listed patent.
No comments:
Post a Comment